Dasotraline - Sumitomo Dainippon Pharma

Drug Profile

Dasotraline - Sumitomo Dainippon Pharma

Alternative Names: DSP-225289; SEP 225289; SEP-0225289; SEP-225289-HCI; SEP-289

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sepracor
  • Developer Sepracor; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Class Amines; Antidepressants; Cyclobutanes; Naphthalenes; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Attention-deficit hyperactivity disorder
  • Phase III Eating disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 25 Jul 2018 Planned Prescription Drug User Fee Act (PDUFA) date for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO) is 2018-08-30
  • 25 Jul 2018 Top-line safety data from the phase III SEP360-321 trial in Eating disorder released by Sunovion Pharmaceuticals
  • 16 May 2018 Sunovion competes enrolment in a phase III trial for Eating disorder in USA (NCT03107026)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top